An evidence-based evaluation of the gastrointestinal safety of coxibs.
about
Efficacy and Safety of COX-2 Inhibitors in the Clinical Management of Arthritis: Mini ReviewCOX-2: where are we in 2003?--distinction from NSAIDs becoming blurredAn economic model of long-term use of celecoxib in patients with osteoarthritisThe coxibs and traditional nonsteroidal anti-inflammatory drugs: a current perspective on cardiovascular risksEffects of the myeloperoxidase 463 gene polymorphisms on development of atrophy in H pylori infected or noninfected gastroduodenal diseaseRofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Evaluation of combined famotidine with quercetin for the treatment of peptic ulcer: in vivo animal study.The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.Approach to managing musculoskeletal pain: acetaminophen, cyclooxygenase-2 inhibitors, or traditional NSAIDs?Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain.Targeting cyclooxygenase-2 in depression is not a viable therapeutic approach and may even aggravate the pathophysiology underpinning depression.Drug-drug interaction between NSAIDS and low-dose aspirin: a focus on cardiovascular and GI toxicity.Selective inhibitors of cyclo-oxygenase-2 (COX-2) induce hypoalgesia in a rat paw model of inflammation.Evidence for the use of non-steroidal anti-inflammatory drugs for acute pain in the post anaesthesia care unit.Comments and Suggestions from Pain Specialists Regarding the CDC's Proposed Opioid Guidelines.
P2860
Q24634894-DCE9F8DC-CB09-4BAB-8D5A-0893157603FBQ24804373-AB8C31BC-2FA1-4475-91E8-61D53EA641A0Q28218005-4CBE1C26-33AD-4916-8246-47FBA2249E7CQ28219195-DDEE4F26-2A79-4E8B-9971-B569E3AC7607Q34099574-5887B7A8-E38F-4F35-A006-8402C02D2093Q35195182-B2227215-9E70-4D67-BBEA-2BAF14593D67Q35618517-D253E232-8B13-4AFD-AE26-D6A9BD45F6F5Q35630102-52AD1BE5-790D-4063-9D50-DBF44B5D7CBDQ35873867-8DDD1CC8-437E-4296-B500-AC7DD8104430Q35942177-24D8F6DE-50A8-43C6-8BB2-BA307A6E53ABQ37987196-7A665995-B7F7-4E56-BA11-9D82CF151B2AQ38024740-24F6185F-DE91-479D-9A42-6CA22EEC085EQ38218184-55B2F30B-9EEE-4F8A-810A-29621D0A8B6CQ41866780-85858118-4D71-4A32-9A5B-6A197B475D2EQ43131760-BA212D75-DCA4-44DA-B908-EDBDC11271BDQ43576588-4BA1DE50-8AB3-4B06-BA36-8B91A5FF67DA
P2860
An evidence-based evaluation of the gastrointestinal safety of coxibs.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@ast
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@en
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@nl
type
label
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@ast
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@en
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@nl
prefLabel
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@ast
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@en
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@nl
P1476
An evidence-based evaluation of the gastrointestinal safety of coxibs.
@en
P2093
Claire Bombardier
P356
10.1016/S0002-9149(02)02231-2
P407
P577
2002-03-01T00:00:00Z